Advancing Biomarker Strategies in Rare Disease: Insights from Our Lunch & Learn

Last week, Sword Bio was proud to host a Lunch & Learn seminar in Cambridge, MA, where more than 20 professionals gathered to discuss one of the most pressing challenges in drug development: clinical biomarker strategy for rare diseases.

We were honored to welcome Binodh DeSilva, Ph.D., Senior Vice President of Bioanalytical and Biomarker Development at Ultragenyx Pharmaceuticals, as our keynote speaker. Dr. DeSilva shared a wealth of expertise on how biomarkers can help accelerate the development of safe and effective therapies for rare diseases.

Understanding the Challenges of Rare Disease Development

Rare diseases often come with unique complexities:

• Many affect pediatric populations.
• Disease progression can be long and subtle, with limited visible clinical changes.
• Novel drug mechanisms may have varying levels of biological validation.
• Standard endpoints—how a patient feels, functions, or survives—are often impractical to measure.

These challenges make traditional development pathways difficult, underscoring the importance of new approaches.

Why Biomarkers Matter

Biomarkers provide a powerful tool to overcome these hurdles by:

• Connecting therapeutic targets with underlying disease mechanisms.
• Offering measurable indicators of drug response.
• Accelerating development timelines for innovative therapies.Dr. DeSilva emphasized that defining the right clinical questions early and establishing a clear context of use are critical to biomarker success. Feasibility, clinical relevance, and clinical utility are the guiding criteria for effective biomarker development .

Key Takeaways from the Discussion

• Start early: Biomarker and sample acquisition strategies should be initiated at the earliest stages of development.
• Work collaboratively: Cross-functional teamwork, and even public–private partnerships, are essential to accelerate progress.
• Manage resources wisely: Precious matrices must be carefully managed, and surrogate options should be considered.
• Consider delivery: The way a therapy is delivered can significantly influence biomarker outcomes.
• Stay focused on the clinic: Always ask which biomarkers are truly relevant to patient care .

Looking Ahead

Biomarker development for rare diseases is not just a scientific challenge—it’s a collaborative one. As Dr. DeSilva highlighted, working together across teams and organizations will be the key to unlocking faster, more effective treatments for patients who need them most.

We are grateful to everyone who joined us for this Lunch & Learn and look forward to hosting future events that bring the community together to exchange ideas and advance innovation.